by ICS-subtype consisting of a ‘fluticasone-group’ (fluticasone propionate or fluticasone furoate) and an ‘MBBC-group’ (mometasone furoate, beclomethasone, budesonide or ciclesonide). The outcome was ...

Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...

Alongside over-the-counter NARCAN ® Nasal Spray 4 mg, prescription KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg will expand Emergent's ability to distribute multiple life-saving opioid overdose ...

NARCAN® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN® Nasal Spray is not a ...

Hikma will continue producing its 8 mg naloxone HCl nasal spray in its Columbus, Ohio manufacturing facility and will provide it to Emergent as its exclusive commercial partner. This partnership ...

Hikma will continue producing its 8 mg naloxone HCl nasal spray in its Columbus, Ohio manufacturing facility and will provide it to Emergent as its exclusive commercial partner. "We are thrilled ...

About NARCAN ® Nasal Spray NARCAN ® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose.

Under the terms of the six-year agreement, Emergent will add KLOXXADO® Nasal Spray to its naloxone product portfolio and will be responsible for all North America product sales and marketing.